Innate Adds To IO Pipeline With Novo's First-In-Class Anti-C5aR Candidate

Phase I candidate already tested in rheumatoid arthritis could be used to optimize the activity of T cells and NK cells in the tumor microenvironment, either in combination with checkpoint inhibitors or as a solo agent.